Tu canal independiente de oncología en español
Regístrate aquí para recibir más contenidos
Registrarse
OncoBites te trae los resúmenes y
presentaciones más relevantes del congreso
ASH 2025
Top resúmenes y presentaciones
CARDINAL: A Phase 1 study of TERN-701, a novel
investigational allosteric BCR::ABL1 inhibitor for patients
with previously treated CML
901
Improved long-term tolerability and efficacy of
asciminib-based combination therapies in newly diagnosed
CML patients - the fascination trial.
903
Somatic mutations at diagnosis in patients with chronic Phase
CML receiving frontline imatinib are associated with a higher
rate of treatment failure: First analysis from the international
CML foundation (iCMLf) genomics alliance on the harmony
platform
75
ASH 2025
LEUCEMIA MIELOIDE CRÓNICA
ASH 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Management and outcomes of patients diagnosed with chronic
myeloid leukemia in blast Phase: A multicenter analysis by the h
jean khoury cure CML consortium
904
International, prospective study comparing nilotinib versus
imatinib with early switch to nilotinib to obtain sustained
treatment-free remission (TFR) in patients with chronic myeloid
leukemia: The tfr rate at the end of follow-up
905
An open label randomized Study of low dose dasatinib (50 mg
OD) vs standard dose dasatinib (100 mg OD) vs standard dose
imatinib (400 mg OD) as upfront therapy in patients with newly
diagnosed chronic myeloid leukemia (CML) - chronic Phase (CP)
5560
Randomized comparison of ponatinib versus imatinib in
combination with chemotherapy in patients 55 years of age
and older with newly diagnosed ph+ ALL: Molecular response
and initial outcome analysis of the EWALL PH03 Study
440
Primary efficacy analysis of phase II study investigating
tyrosine kinase inhibitor (TKI) and inotuzumab
ozogamicin-based therapy for newly diagnosed
Philadelphia-chromosome positive acute lymphoblastic
leukemia (Ph+ ALL)
441
First results of the Phase III GIMEMA ALL2820 trial comparing
ponatinib plus blinatumomab to imatinib and chemotherapy
for newly diagnosed adult ph+ acute lymphoblastic leukemia
patients
439
ASH 2025
LEUCEMIA LINFOBLÁSTICA AGUDA
ASH 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
Inotuzumab ozogamicin then blinatumomab for older adults
with newly diagnosed, ph-negative, CD22-positive, B-cell acute
lymphoblastic leukemia: Extended follow-up of alliance for
clinical trials in oncology A041703 cohort 1 reveals durable
remission and survival
444
Blinatumomab mitigates the impact of traditional adverse
prognosticators among children with standard risk B-acute
lymphoblastic leukemia: Updated results of the Children’s
Oncology Group (COG) Trial AALL1731
758
Genomic determinants of treatment outcome and
identification of a new genomic subset of adult acute
lymphoblastic leukemia from the ECOG-ACRIN E1910
randomized phase III trial
31
Safety and efficacy of surovatamig (AZD0486) in adolescent
and adult patients with relapsed or refractory (R/R) B-cell
acute lymphoblastic leukemia (B-ALL): Updated results
from the Phase 1/2 SYRUS study
3345
Blinatumomab consolidation in high-risk Philadelphia
chromosome-negative B-cell acute lymphoblastic leukemia in
adults: Final report of the GRAALL-2014/B-QUEST study
643
ASH 2025
LEUCEMIA LINFOBLÁSTICA AGUDA
ASH 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse
CD19-CAR T cell therapy as a definitive consolidation in older
adults with B-ALL in CR1 is safe and induces durable MRD-
remission
443
Single CAR-t infusion during front-line consolidation induces
deep and sustained remission in newly diagnosed adult ph+b-
ALL: A prospective phase 2 study
442
Phase 3 randomized study of teclistamab plus daratumumab
versus investigator’s choice of daratumumab and
dexamethasone with either pomalidomide or Bortezomib
(DPd/DVd) in patients (Pts) with relapsed refractory multiple
myeloma (RRMM): Results of majestec-3
LBA-6
BCMA CAR T-cell therapy in newly diagnosed primary
plasma cell leukemia ineligible for transplantation: An open
label, single-arm, phase 2 study (CAREMM-002)
257
Minimal residual disease (MRD)-negative outcomes following a
novel, in vivo gene therapy generating anti–B-cell maturation
antigen (BCMA) chimeric antigen receptor (CAR)-T cells in
patients with relapsed and refractory multiple myeloma (RRMM):
Preliminary results from inMMyCAR, the first-in- human phase 1
study of KLN-1010 Category: 700s - Transplantation and Adoptive
Cell Therapies
LBA-1
ASH 2025
MIELOMA MÚLTIPLE
ASH 2025
Tu canal independiente de oncología en español
Top resúmenes y presentaciones
Regístrate aquí para recibir más contenidos
Registrarse